Evidence mapPaperPMID 41824218Full record

ReviewPain and therapy2026

Acetyl-L-Carnitine in the Treatment of Peripheral Neuropathies: A Narrative Review.

Diego Maria Michele Fornasari

Abstract readReview
In one paragraph

Review in Pain and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Diego Maria Michele FornasariDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano "La Statale", Milan, Italy. diego.fornasari@unimi.it.ORCID http://orcid.org/0000-0002-9668-3103

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acetyl-L-carnitine is an ester of L-carnitine, both endogenous molecules, with a vital role in lipid metabolism. Exogenously delivered acetyl-L-carnitine is endowed with neuroprotective and neurotrophic actions due to its antioxidant and metabolic properties. Moreover, acetyl-L-carnitine is an epigenetic regulator of genes involved in analgesia such as the metabotropic glutamate 2 receptor in the presynaptic neurons and of neurotrophic factors including nerve growth factor. Accordingly, its long-term neurotrophic and analgesic activity has been confirmed in animal models of chronic inflammatory and neuropathic pain and in clinical studies in patients with peripheral neuropathies. The aim of this narrative review was to summarise the available evidence on the usefulness of acetyl-L-carnitine in the treatment of peripheral neuropathies.

Indexed as

Acetyl-l-carnitineEpigenetic drugsNeuropathic pain

Identifiers

PMID41824218
PMCPMC13172195

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.